These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12413806)

  • 1. Models and methods for studying insurmountable antagonism.
    Vauquelin G; Van Liefde I; Vanderheyden P
    Trends Pharmacol Sci; 2002 Nov; 23(11):514-8. PubMed ID: 12413806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights in insurmountable antagonism.
    Vauquelin G; Van Liefde I; Birzbier BB; Vanderheyden PM
    Fundam Clin Pharmacol; 2002 Aug; 16(4):263-72. PubMed ID: 12570014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the potency and molecular mechanism of action of insurmountable antagonists.
    Kenakin T; Jenkinson S; Watson C
    J Pharmacol Exp Ther; 2006 Nov; 319(2):710-23. PubMed ID: 16857731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model.
    Robertson MJ; Dougall IG; Harper D; McKechnie KC; Leff P
    Trends Pharmacol Sci; 1994 Oct; 15(10):364-9. PubMed ID: 7809951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effect of KT3-671, a nonpeptide angiotensin-receptor antagonist, on rabbit and rat isolate vascular smooth muscles: a possible involvement of K(ATP) channels.
    Satake N; Imanishi M; Keto Y; Ishikawa M; Yamada H; Shibata S; Tomiyama A
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):457-67. PubMed ID: 10710133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753.
    Wong PC; Timmermans PB
    J Pharmacol Exp Ther; 1991 Jul; 258(1):49-57. PubMed ID: 2072311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The assessment of antagonist potency under conditions of transient response kinetics.
    Christopoulos A; Parsons AM; Lew MJ; El-Fakahany EE
    Eur J Pharmacol; 1999 Oct; 382(3):217-27. PubMed ID: 10556673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of receptor interactions of agonists and antagonists.
    Kenakin T
    Curr Protoc Pharmacol; 2008 Sep; Chapter 4():Unit 4.1. PubMed ID: 22294222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional and binding studies of insurmountable antagonism of 606A, a novel AT1-receptor antagonist in rabbit tissues.
    Kurosawa Y; Minami K; Hashimoto Y; Narita H
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):132-8. PubMed ID: 10413079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of human cannabinoid 1 (CB1) receptor antagonists: Structure-kinetics relationships (SKR) and implications for insurmountable antagonism.
    Xia L; de Vries H; Yang X; Lenselink EB; Kyrizaki A; Barth F; Louvel J; Dreyer MK; van der Es D; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2018 May; 151():166-179. PubMed ID: 29102677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.
    Vauquelin G; Fierens F; Van Liefde I
    J Hypertens Suppl; 2006 Mar; 24(1):S23-30. PubMed ID: 16601569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism.
    Kohout TA; Xie Q; Reijmers S; Finn KJ; Guo Z; Zhu YF; Struthers RS
    Mol Pharmacol; 2007 Aug; 72(2):238-47. PubMed ID: 17409285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism.
    Panek RL; Lu GH; Overhiser RW; Major TC; Hodges JC; Taylor DG
    J Pharmacol Exp Ther; 1995 May; 273(2):753-61. PubMed ID: 7752078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An alternative model for non-competitive antagonism.
    Brandt HD; Offermeier J
    Arch Int Pharmacodyn Ther; 1977 Feb; 225(2):180-95. PubMed ID: 849068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation.
    Vauquelin G; Szczuka A
    Neurochem Int; 2007 Oct; 51(5):254-60. PubMed ID: 17606314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
    Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
    Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
    Bissantz C; Bohnert C; Hoffmann T; Marcuz A; Schnider P; Malherbe P
    J Med Chem; 2012 Jun; 55(11):5061-76. PubMed ID: 22574973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism.
    Van Liefde I; Vauquelin G
    Mol Cell Endocrinol; 2009 Apr; 302(2):237-43. PubMed ID: 18620019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell recombinant pharmacology: bovine alpha(1a)-adrenoceptors in rat-1 fibroblasts release intracellular ca(2+), display subtype-characteristic agonism and antagonism, and exhibit an antagonist-reversible inverse concentration-response phase.
    Pediani JD; MacKenzie JF; Heeley RP; Daly CJ; McGrath JC
    J Pharmacol Exp Ther; 2000 Jun; 293(3):887-95. PubMed ID: 10869389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
    Vanderheyden PM; Fierens FL; Vauquelin G
    Biochem Pharmacol; 2000 Dec; 60(11):1557-63. PubMed ID: 11077037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.